Afinitor FDA Approval History
FDA Approved: Yes (First approved March 30, 2009)
Brand name: Afinitor
Generic name: everolimus
Dosage form: Tablets
Company: Novartis AG
Treatment for: Renal Cell Carcinoma, Breast Cancer, Neuroendocrine Carcinoma
Afinitor (everolimus) is an oral once-daily inhibitor of mTOR indicated for the treatment of patients with advanced HR+, HER2- breast cancer; progressive neuroendocrine tumors of pancreatic origin (PNET); progressive neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin; advanced renal cell carcinoma; and subependymal giant cell astrocytoma (SEGA) and renal angiomyolipomas associated with tuberous sclerosis.
Development Timeline for Afinitor
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.